– IPO planned at a reference price of €0.817/share
– Fundraising in the amount of €8 million, guaranteed by OPM management, planned before the end of 2022
– Availability of the Information Document relating to OPM
Dijon (France), September 28, 2022 at 6:00 p.m. – Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign (ALONC – FR0011766229) and Oncodesign announce that Euronext Paris SA has authorized on September 26, 2022 the admission to listing on the Euronext Access + market in Paris of the ordinary shares of OPM, according to the direct listing procedure within the framework of the allocation of OPM shares to Oncodesign shareholders. This allocation remains subject to approval by Oncodesign’s general meeting to be held in Dijon on September 30, 2022.
To receive information from ONCOSIGN in real time, send a request to [email protected]